METTL3 and neoplasm: METTL3 KD reduces methylation levels, accelerates apoptosis, reduces hyperplasia, and inhibits tumor growth in various cancers (acute myeloid leukemia; glioblastoma; uveal melanoma; osteosarcoma; oral, head and neck, and cutaneous squamous cell carcinoma; nasopharyngeal carcinoma; and breast, liver, bladder, gastric, prostate, lung, colorectal, pancreatic, thyroid, and ovarian cancer) [132–151].